On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $173.52 which represents a decrease of $-0.27 or -0.16% from the prior close of $173.79. The stock opened at $173.22 and touched a ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Fintel reports that on October 31, 2024, Morgan Stanley downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...

Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to Equal Weight and slashed the price target from $285 to $204.

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

The biotech firm reported Q3 earnings per share (EPS) of $4.08, surpassing analyst expectations of $3.77. Revenue came in at $2.47 billion, slightly above the consensus estimate of $2.43 billion.

Despite challenges in key segments, Biogen Inc (BIIB) raises EPS guidance and showcases promising growth in its rare disease franchise and pipeline potential.

At this time, I would like to welcome everyone to the Biogen third quarter 2024 earnings call and business update. [Operator ...

Biogen raised its full-year guidance and now expects adjusted EPS to range from $16.10 to $16.60, up from prior guidance of $15.75 to $16.25. It still expects revenue to fall by a low-single-digit ...